Funding secured to keep R&D moving forward
Argent BioPharma (ASX: RGT) has entered into two loan facility agreements totalling US$500,000 in aggregate working capital, with lenders WVP Emerging Manager Onshore Fund LLC – C/M Capital Series and C/M Capital Master Fund, LP.
Each lender has agreed to provide a facility of up to US$250,000, with proceeds earmarked for corporate costs and research and development activities.
When big ASX news breaks, our subscribers know first
Key terms of the loan facility
The key terms of the two facilities are as follows:
- Non-revolving cash advance facility with a single drawdown per facility
- 9-month repayment term after drawdown, or on another date agreed in writing
- Repayment amount: US$287,500 per facility, with no ongoing interest charges
- Unsecured facilities — no company assets pledged as collateral
- Default interest: 18% per annum on overdue amounts
- Early repayment trigger: if the Company completes a capital raise of at least A$5.0 million from third parties (excluding funds advanced under the Convertible Securities Agreements), each Lender may require repayment within 15 business days of written notice
Each Lender is already a counterparty to a convertible securities agreement with the Company. In connection with the Loan Facilities, each Lender has consented to the Company incurring this indebtedness and has waived its rights under the relevant provisions of those agreements. The Lenders are not related parties or substantial holders of the Company, maintaining the arms-length nature of the transaction.
The two facilities are summarised in the table below:
| Facility | Lender | Limit | Repayment Amount | Term |
|---|---|---|---|---|
| Facility 1 | WVP Emerging Manager Onshore Fund LLC – C/M Capital Series | US$250,000 | US$287,500 | 9 months after drawdown |
| Facility 2 | C/M Capital Master Fund, LP | US$250,000 | US$287,500 | 9 months after drawdown |
What is a non-revolving loan facility, and why does it matter?
A non-revolving cash advance facility means funds are drawn down once in a single transaction, rather than accessed repeatedly as needed — unlike a revolving credit line, where a borrower can draw, repay, and redraw funds up to a set limit. For investors, the distinction matters because it sets a defined and predictable repayment obligation from the outset.
The unsecured nature of these facilities is also worth noting. Because no company assets have been pledged as collateral, Argent BioPharma preserves its financial flexibility. The structure provides working capital runway without diluting shareholders through an equity raise or encumbering the Company’s intellectual property assets at this stage.
Runway to advance CimetrA® and the broader pipeline
The secured funding supports Argent BioPharma’s broader strategic mission as a revenue-generating specialty biopharmaceutical company. The Company’s portfolio is anchored by CimetrA®, its first-in-class immune-modulating platform targeting inflammatory and autoimmune diseases, alongside proprietary NanoBodies™ technologies. Argent BioPharma also generates recurring royalty income through the global licensing of CannEpil®, underpinning a capital-efficient commercialisation model.
The NLC antiviral licence secured in September 2026 extended this capital-efficient model further, adding worldwide commercialisation rights to three immune-modulation products under a tiered royalty structure that shares costs across both the NLC portfolio and the CimetrA programme.
The Company has described a clear pathway toward expansion into United States capital markets, though no specific timeline for this has been indicated. In the near term, the US$500,000 loan facility extends operational runway as the Company continues to advance its pipeline and pursue its next capital milestone. The A$5.0 million capital raise threshold embedded in the early repayment trigger serves as a natural signpost for the Company’s next financing objective, giving investors a marker to watch as Argent BioPharma progresses its commercial and R&D activities.
Don’t Miss the Next ASX Healthcare Breakout
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market and never miss a critical announcement. Click the “Free Alerts” button at Big News Blast to start receiving real-time alerts the moment news breaks.